StreetInsider.com News Articles

Form 8-K ALLURION TECHNOLOGIES, For: Jun 12

Wed, 17 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260617/26660498.html

Form 8-K ALLURION TECHNOLOGIES, For: Jun 12

Wed, 17 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260617/26660498.html

Allurion announces 1-for-15 reverse stock split ahead of re-listing

Wed, 17 Jun 2026 16:05:29 -0400

Allurion Technologies, Inc. (OTCQB: ALUR) announced a 1-for-15 reverse stock split of its outstanding common stock, set to take effect at 12:01 a.m. Eastern Time on June 18, 2026, according to a press release from the company.

The move is intended to support regaining compliance with the continued listing requirements of the New York Stock Exchange (NYSE) or the initial listing requirements of the NYSE American.

Under the terms of the reverse stock split, every 15 issued shares of common stock will be combined into one share, with no change to the par value per share. This will reduce outstanding shares from

Allurion announces 1-for-15 reverse stock split ahead of re-listing

Wed, 17 Jun 2026 16:05:29 -0400

The move is intended to support regaining compliance with the continued listing requirements of the New York Stock Exchange (NYSE) or the initial listing requirements of the NYSE American.

Under the terms of the reverse stock split, every 15 issued shares of common stock will be combined into one share, with no change to the par value per share. This will reduce outstanding shares from

Allurion Advances Plan to Re-List

Wed, 17 Jun 2026 16:05:00 -0400

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (OTCQB: ALUR), a pioneer in metabolically healthy weight loss, today announced a 1-for-15 reverse stock of its outstanding common stock intended to support regaining compliance with the continued listing requirements of the New York Stock Exchange (the “NYSE”) or initial listing requirements of the NYSE American.

Allurion continues to actively engage with national exchanges and is advancing its re-listing strategy as part of a comprehensive plan to strengthen its capital markets positioning.

“We have had a constructive and collaborative dialogue with the national exchanges throughout this process, and we remain focused on meeting

Allurion Advances Plan to Re-List

Wed, 17 Jun 2026 16:05:00 -0400

Allurion continues to actively engage with national exchanges and is advancing its re-listing strategy as part of a comprehensive plan to strengthen its capital markets positioning.

“We have had a constructive and collaborative dialogue with the national exchanges throughout this process, and we remain focused on meeting

Allurion Advances Plan to Re-List

Wed, 17 Jun 2026 16:05:00 -0400

Allurion continues to actively engage with national exchanges and is advancing its re-listing strategy as part of a comprehensive plan to strengthen its capital markets positioning.

“We have had a constructive and collaborative dialogue with the national exchanges throughout this process, and we remain focused on meeting

Allurion Advances Plan to Re-List

Wed, 17 Jun 2026 16:05:00 -0400

Allurion continues to actively engage with national exchanges and is advancing its re-listing strategy as part of a comprehensive plan to strengthen its capital markets positioning.

“We have had a constructive and collaborative dialogue with the national exchanges throughout this process, and we remain focused on meeting

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (OTCQB: ALUR), a pioneer in metabolically healthy weight loss, today announced successful early traction in the launch of the Allurion Program in the United States, marked by strong clinical outcomes, rapid account growth, high re-order rates, and performance exceeding internal expectations.

First shipments of the Allurion Smart Capsule were completed in April, with the first U.S. patients treated that same month. Early clinical outcomes have been highly encouraging, with patients losing between 8–11% of their total body weight in just the first four weeks, reinforcing the program’s potential to deliver rapid, meaningful

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

Form 8-K ALLURION TECHNOLOGIES, For: May 20

Wed, 27 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260527/26558528.html

Form 8-K ALLURION TECHNOLOGIES, For: May 20

Wed, 27 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260527/26558528.html

Form 10-Q ALLURION TECHNOLOGIES, For: Mar 31

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506601.html

Form 10-Q ALLURION TECHNOLOGIES, For: Mar 31

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506601.html

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection point that formally launches the company into the world’s largest and most dynamic obesity market.

Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following discontinuation. These early patient profiles reinforce Allurion’s positioning as a compelling, non-surgical, non-pharmaceutical option that delivers fast weight loss results within the rapidly evolving obesity treatment landscape.

Early feedback from trained

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

Early feedback from trained

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

Early feedback from trained

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

Early feedback from trained

Form 10-K ALLURION TECHNOLOGIES, For: Dec 31

Mon, 30 Mar 2026 08:31:00 -0400

http://archive.fast-edgar.com/20260330/AI22H22DZW2RT9Z222262ZYRVUJJYZ223282

Filed on: March 30, 2026

Form 10-K ALLURION TECHNOLOGIES, For: Dec 31

Mon, 30 Mar 2026 08:31:00 -0400

http://archive.fast-edgar.com/20260330/AI22H22DZW2RT9Z222262ZYRVUJJYZ223282

Filed on: March 30, 2026

Form 8-K ALLURION TECHNOLOGIES, For: Mar 06

Thu, 12 Mar 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260312/26154480.html

Form 8-K ALLURION TECHNOLOGIES, For: Mar 06

Thu, 12 Mar 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260312/26154480.html

Allurion appeals NYSE delisting, cites FDA approval in compliance plan

Thu, 12 Mar 2026 16:16:37 -0400

Allurion Technologies Inc. (OTCID: ALUR) has appealed the New York Stock Exchange's decision to initiate delisting proceedings against the company's securities, according to a company statement.

The NYSE moved to delist Allurion under Section 802.01B of its Listed Company Manual, which requires listed companies to maintain an average global market capitalization of at least $15 million over a consecutive 30 trading day period.

Allurion received FDA approval for its Gastric Balloon System on February 20, 2026, and has developed a plan to regain NYSE compliance or seek listing on NYSE American. The company has shared this plan with the NYSE and is